Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr Andorsky on Molecular Responses With Second-Line Asciminib in CP-CML

April 10th 2025

David J. Andorsky, MD, discusses molecular responses achieved with asciminib dose escalation in patients with CP-CML who had received 1 prior TKI.

Dr Ahmed on the Rationale for Evaluating NTKR-255 After CAR T-Cell Therapy in R/R LBCL

April 10th 2025

Sairah Ahmed, MD, explains the rationale for evaluating NTKR-255 after CAR T-cell therapy in relapsed/refractory large B-cell lymphoma.

Investigational Microbiotherapy MaaT033 Is Safe in Allo-HSCT Recipients

April 9th 2025

An independent DSMB found MaaT033 to have a favorable safety profile in patients with hematologic malignancies undergoing allo-HSCT in the PHOEBUS trial.

Tambiciclib Generates Potential OS Benefit in R/R AML

April 8th 2025

Tambiciclib generated a median overall survival of 8.8 months in patients with relapsed/refractory acute myeloid leukemia.

FDA Approval Is Sought for Ziftomenib in NMP1-Mutant R/R AML

April 8th 2025

The FDA has received an NDA for ziftomenib in relapsed/refractory NMP1-mutant acute myeloid leukemia.

Five Under 5: Top Oncology Videos for the Week of 3/30

April 6th 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, ovarian cancer, prostate cancer, breast cancer, and follicular lymphoma.

The OncFive: Top Oncology Articles for the Week of 3/30

April 5th 2025

Orca-T boosts cGVHD-free survival in hematologic malignancies, cilta-cel continues to impress in CARTITUDE-4, and more.

Oral Decitabine/Cedazuridine Is an Effective, At-Home Treatment Option for MDS and CMML

April 5th 2025

James K. McCloskey II, MD, discusses the advantages of the oral formulation of decitabine plus cedazuridine for patients with MDS and CMML.

FELIX Analysis Suggests Consolidative SCT After Obe-Cel Does Not Improve EFS/OS in R/R B-ALL

April 4th 2025

A small sample size from an analysis of the FELIX trial suggests consolidative SCT may not be needed after obe-cel treatment in relapsed/refractory B-ALL.

Chemotherapy-Free Combos Lead the Way in R/R Follicular Lymphoma

April 4th 2025

OncologyLive was onsite at the 2024 ASH Annual Meeting to film a Peer Exchange featuring expert commentary on follicular lymphoma.

Dr Farid on the Efficacy of MDC-CAR-BCMA001 in R/R Myeloma and AL Amyloidosis

April 3rd 2025

Kiavasch Mohammad Nejad Farid, MD, discusses the efficacy of MDC-CAR-BCMA001 in relapsed/refractory multiple myeloma and systemic light chain (AL) amyloidosis.

Single-Center Experience Highlights Utility of CD19-Directed CAR T-Cell Therapy in B-Cell Malignancies

April 3rd 2025

Real-world data with axi-cel, tisa-cel, and brexu-cel in patients with B-cell malignancies proved comparable to other experiences with cellular therapy.

Updated ALLELE Data Confirm Clinical Benefit of Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease

April 2nd 2025

Tabelecleucel generated high response rates and favorable OS in patients with EBV-positive PTLD who had progressed on prior standard-of-care approaches.

Dr Vose on the Optimal Role for Epcoritamab in Relapsed/Refractory LBCL

April 2nd 2025

Julie M. Vose, MD, MBA, discusses the optimal use of epcoritamab for select patients with relapsed/refractory large B-cell lymphoma.

Pacritinib Elicits Early Responses in Multi-Refractory Chronic Graft-Vs-Host Disease

April 2nd 2025

Pacritinib was active and safe in patients with multi-refractory chronic graft-vs-host disease.

Axi-Cel Is Associated With Higher ORR, Increased CRS/ICANS vs Tisa-cel in Older Patients With R/R DLBCL

April 2nd 2025

Axi-cel led to higher response rates but increased toxicity vs tisa-cel in older patients with relapsed/refractory DLBCL.

Axatilimab After Second-Line Therapy Generates ORR Benefit in Steroid-Refractory cGVHD

April 2nd 2025

A consistent ORR was shown with axatilimab after second-line therapy, regardless of prior lines of therapy, in patients with steroid-refractory cGVHD.

ICANS, Corticosteroid Use Identified As Risk Factors for NRM-Associated Infections After Axi-Cel Infusion in R/R NHL

April 2nd 2025

Infections occur early after CAR T-cell therapy administration in patients with relapsed/refractory NHL.

Orca-T Boosts cGVHD-Free Survival vs Allo-HSCT in Advanced Hematologic Malignancies

April 2nd 2025

Orca-T improved moderate-to-severe cGVHD–free survival vs conventional allogenic transplant in advanced hematologic malignancies.

Comparative Analysis Shows ORR, OS Benefits With Obe-Cel in R/R B-ALL

April 1st 2025

Obe-cel showed higher response rates and longer survival vs non–CAR T therapies in adults with R/R B-ALL.